Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Professor of Musculoskeletal and Surgical Science, David Beard, has been awarded an Honorary Fellowship by the British Orthopaedic Association.

Horizontal portrait of David Beard

An Honorary Fellowship is the highest honour that the BOA (British Orthopaedic Association) can confer. It was awarded to Professor Beard in recognition of his outstanding contribution and achievements in research across the Trauma and Orthopaedic spectrum leading to improvements in patient care.

Professor Beard is one of the nominated Royal College of Surgeons (Eng) Surgical Trials chairs and Rosetrees Director of the Surgical Intervention Trials Unit (SITU-NDORMS) being responsible for a portfolio of surgical and complex intervention trials, many as co-applicant and some as Chief Investigator.

He is currently researching the introduction of robotic surgery in the NHS, surgical clinical trials methodology, including placebo control designs, and a host of musculoskeletal intervention efficacy studies. He is also involved in several international surgical trials and and supervises postgraduate students within NDORMS.

On being awarded the Honorary Fellowship, Professor Beard said;  

“I am very privileged and honoured to be given such a prestigious Fellowship by the BOA, especially in my core discipline, orthopaedic science. Like most personal awards the letters and certificate may point to a single name but it simply would not happen without the support and help from a set of first rate colleagues both in the Department and around the country.  To me it is very much a shared team award reflecting and recognising the success of orthopaedic/MSK research in Oxford (and the UK) over many years. Similar to everyone in NDORMS, I shall continue to do my very best research under the overall umbrella of improving healthcare, but it would give added satisfaction to see NDORMS remaining in the very top flight of those pursuing such an endeavour.” 

Similar stories

Fiona Powrie honoured by British Society for Immunology

Fiona Powrie was one of four researchers from the University of Oxford recognised for their outstanding contributions to immunology with Honorary Lifetime Membership of the British Society for Immunology.

The Kennedy Institute scoops sustainability award

A new roof extension was awarded the 2021 Green Award for Sustainability by the Oxford Preservation Trust alongside a Certificate in the New Building category.

Vaccination safety: generating accurate evidence is the clearest path to creating public trust

A new study shows that a vaccine surveillance method in observational data may generate high number of false positives

Fiona Powrie appointed new Deputy Chair of Wellcome’s Board of Governors

Fiona Powrie, Director of the Kennedy Institute of Rheumatology at the University of Oxford has been selected as the next Deputy Chair of Wellcome’s Board of Governors.

A drug being trialled to treat cancer, could be the key to reducing gut inflammation

Published in Nature Communications, a new study reveals a new signalling pathway behind macrophage inflammatory activity

Single-cell ancestry vaccine research funded by the Chan Zuckerberg Initiative

The Chan Zuckerberg Initiative (CZI) has provided $2 million in funding to investigate how our ancestry and diversity influence the way that vaccines work in our cells.